Status:

COMPLETED

Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers

Lead Sponsor:

Medical University of South Carolina

Conditions:

Nicotine Dependence

Eligibility:

All Genders

21-60 years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate the impact of varenicline treatment on cue induced craving to smoking using brain imaging. The investigators hypothesize that participants will report reduced ...

Detailed Description

Treatment with varenicline reduces overall subjective cigarette craving and smoking reward in nicotine-dependent smokers. This preliminary study will explore the impact of varenicline treatment on smo...

Eligibility Criteria

Inclusion

  • Age 21 - 60 treatment-seeking right handed smokers.
  • Meet criteria for primary nicotine dependence confirmed by FTND and smoked at least 70% of days in the last 30 days prior to assessment.
  • General good health confirmed by history \& physical.
  • Able to read and understand questionnaires and informed consent.
  • Motivated to quit, willing to set a target quit date (TQD) and abstain from smoking after TDQ.
  • Participants must have a negative urine drug screen (UDS) and pregnancy test prior to imaging sessions and beginning varenicline treatment.
  • Female participants will use a reliable method of birth control throughout the study.
  • Demonstrate subjective response to cues in a laboratory cue reactivity session.

Exclusion

  • Currently meets DSM-IV criteria for any other psychoactive substance dependence disorder except nicotine dependence.
  • Any psychoactive substance abuse within the last 30 days as evidenced by subject report or urine drug screen.
  • Use of other tobacco products.
  • Current use of nicotine replacement therapy, bupropion, or other smoking cessation treatment.
  • Previous failed attempt on varenicline.
  • Meets DSM-IV criteria for current axis I disorders of major depression, panic disorder, obsessive compulsive disorder, post-traumatic stress syndrome, bipolar affective disorder, schizophrenia, or any other psychotic disorder or organic mental disorder.
  • Current suicidal ideation with plan or homicidal ideation.
  • Need for maintenance or acute treatment with any psychoactive medication including anti-seizure medications which could potentially interfere with fMRI.
  • Clinically significant medical problems that would impair participation or limit ability to participate in scan.
  • Sexually active females of child-bearing potential who are pregnant, nursing, or who are not using a reliable form of birth control.
  • Has current charges pending for a violent crime (not including DUI related offenses).
  • Persons with ferrous metal implants or pacemaker since fMRI will be used.

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2012

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT00934024

Start Date

April 1 2009

End Date

January 1 2012

Last Update

December 10 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University of South Carolina

Charleston, South Carolina, United States, 29425